Table 2. Efficacy Measures (Modified Intention-to-Treat Set).

End point	Placebo (n = 144)	Atropine, 0.01% (n = 133)	Atropine, 0.02% (n = 212)
Responder analysis: <0.50 D myopia progression at month 36
No. of eyes	252	200	366
No. (%) of responder eyes	44 (17.5)	57 (28.5)	81 (22.1)
Odds ratio for low-dose atropine/placebo (95% CI)	NA	4.54 (1.15 to 17.96)	1.77 (0.50 to 6.26)
P value	NA	.03	.37
Cycloplegic refraction: mean change from baseline in SER
Baseline
No. of eyes	282	266	424
Mean SER (SD), D	−2.45 (1.13)	−2.41 (1.17)	−2.42 (1.17)
Median (IQR)	−2.38 (1.66)	−2.20 (1.53)	−2.26 (1.57)
Month 36
No. of eyes	252	200	366
Mean SER (SD), D	−3.72 (1.42)	−3.41 (1.49)	−3.61 (1.53)
Median (IQR)	−3.73 (2.05)	−3.28 (2.02)	−3.51 (2.10)
Least squares mean change (95% CI) from baseline at month 36, D	−1.28 (−1.37 to −1.19)	−1.04 (−1.14 to −0.94)	−1.18 (−1.26 to −1.10)
Least squares mean difference (95% CI) between low-dose atropine and placebo, D	NA	0.24 (0.11 to 0.37)	0.10 (−0.02 to 0.22)
P value	NA	<.001	.10
Biometric measure: mean change from baseline in axial length
Baseline
No. of eyes	281	266	419
Mean axial length (SD), mm	24.33 (0.84)	24.37 (0.81)	24.30 (0.87)
Median (IQR)	24.40 (1.20)	24.39(1.09)	24.29 (1.14)
Month 36
No. of eyes	252	200	366
Mean axial length (SD), mm	25.09 (0.88)	25.12 (0.87)	25.01 (0.98)
Median (IQR)	25.13 (1.29)	25.09 (1.27)	25.01 (1.26)
Least squares mean change (95% CI) from baseline at month 36, mm	0.81 (0.76 to 0.85)	0.68 (0.63 to 0.72)	0.73 (0.69 to 0.76)
Least squares mean difference (95% CI) between low-dose atropine and placebo, mm	NA	−0.13 (−0.19 to −0.07)	−0.08 (−0.13 to −0.02)
P value	NA	<.001	.005

Abbreviations: D, diopter; NA, not applicable; SER, spherical equivalent refractive error.